Market Highlights
According to MRFR analysis, the
global Post-Traumatic Stress Disorder (Ptsd) Market is expected to register a CAGR of 4.8% during the forecast
period of 2019 to 2025 and was valued at USD 7.3 billion in 2018.
Post-Traumatic Stress Disorder
(PTSD) develops when a person is exposed to a traumatic event such as warfare,
violent sexual assault, or other severe threats on a person’s life. A person
with PTSD is at a higher risk for suicide and intentional self-harm. Children
under the age of 10 are less likely to develop PTSD than adults. Prevention is
possible when therapy is targeted at those with early symptoms but is not valid
when carried out among all people following trauma. The chief treatments for
people with PTSD are counseling and medication.
The global post-traumatic stress
disorder (PTSD) market is currently dominated by several market players. The
key players are involved in product launches and strategic collaborations to
strengthen their market positions.
Regional Analysis
The market has been divided, by
region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to be the largest market owing to the increasing
prevalence of PTSD and rising per capita healthcare expenditure. The
post-traumatic stress disorder (PTSD) market in the Americas has further been
branched into North America and Latin America, with the North American market
divided into the US and Canada. The European post-traumatic stress disorder
(PTSD) market has been categorized as Western Europe and Eastern Europe. The
Western European market has further been classified as Germany, France, the UK,
Italy, Spain, and the rest of Western Europe. The post-traumatic stress
disorder (PTSD) market in Asia-Pacific has been segmented into Japan, China,
India, South Korea, Australia, and the rest of Asia-Pacific. The Asia Pacific
region is the fastest region due to the increasing cases of sexual assault and
road accidents and raising awareness about the treatment methods. The
post-traumatic stress disorder (PTSD) market in the Middle East &
Africa has been divided into the Middle East and Africa.
Segmentation
The global post-traumatic stress
disorder (PTSD) market has been segmented based on treatment and end user.
The market, based on treatment, has
been divided into psychotherapy and medication. The psychotherapy has been
further segmented into cognitive therapy, exposure therapy, and eye movement
desensitization and reprocessing (EMDR). The medication has been segmented into
antidepressants, anti-anxiety medications, and prazosin. The antidepressants
are classified as paroxetine, sertraline, mirtazapine, and
amitriptyline, or phenelzine. The anti-anxiety drugs have been classified as
beta-blockers and benzodiazepines. The medication segment is expected to hold
the largest segment during the forecasted period.
The end user segment of the market are
hospitals and clinics, ambulatory surgical centers, and others. The hospitals
and clinics segment is expected to hold the largest share of the market as
these centers are the primary locations for patients receiving treatment and
surgery.
Access Report Details @ https://www.marketresearchfuture.com/reports/post-traumatic-stress-disorder-market-8376
Key Players
Some of the key players
in the global post-traumatic stress disorder
(PTSD) market are Azevan Pharmaceuticals
(US), Marinus Pharmaceuticals, Inc. (US), Bionomics (Australia), Greenstone LLC
(US), GlaxoSmithKline (UK), Pfizer (US), Eli Lilly and Company (US), H.
Lundbeck A/S (Denmark), Tonix Pharmaceuticals Holding Corp. (US), and Mylan NV
(US).
No comments:
Post a Comment